Apyx Medical Corporation

$ 4.11 -2.38 %

Apyx Medical Corporation, an energy technology firm established in 1982 and headquartered in Clearwater, Florida, focuses on the development, manufacturing, and global sale of medical devices for both the aesthetic and surgical fields. The company operates through two main divisions: Advanced Energy and Original Equipment Manufacturing (OEM). Among its key innovations is the Helium Plasma Generator, which delivers a controlled combination of RF energy and helium to precisely cut, coagulate, and ablate soft tissue in open and laparoscopic surgical procedures. For the cosmetic surgery market, Apyx Medical offers its Renuvion product line, enabling plastic surgeons and other aesthetic practitioners to apply targeted heat for desired patient outcomes. Concurrently, the J-Plasma brand caters specifically to the hospital surgical sector. Furthermore, the company designs, produces, and sells disposable hand pieces, alongside OEM generators and their related accessories. The entity was previously known as Bovie Medical Corporation, changing its name to Apyx Medical Corporation in January 2019.

CEO: Charles D. Goodwin - https://www.apyxmedical.com

Price objectif

$6 45.99 %

Recommandation

Buy

DCF

$ -4.96

Loading data...

APYX vs S&P500

Loading data...

No data available.

Quick ratio

4.79

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

-18.68

may indicate that the company is undervalued or has poor growth prospects.

EPS

-0.22

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-90.62 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-7.97 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

11.36

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

3.08

means it relies more on debt, which can increase financial risk.

Free cash flow per share

-0.21

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
3 indicates worrying financial health
Altman score
1.63 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
3.30 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.63 indicates a moderate level of debt, which is generally acceptable but may present some risk
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.